The transcription factor RIP140 regulates interferon γ signaling in breast cancer
International Journal of Cancer · 2025-07 · 157 (1) · 170-182
DOI: 10.1002/ijc.35405 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 10.03.2025. Verfasst von Stéphan Jalaguier und 9 weiteren Autor:innen. Beteiligte Einrichtung: IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France. Hauptthemen laut MEDLINE: Breast Neoplasms, Interferon-gamma, Signal Transduction, Nuclear Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Groupement des Entreprises Françaises dans la lutte contre le Cancer.
Abstract (Originalsprache)
RIP140 (receptor interacting protein of 140 kDa) is an important player in breast cancer (BC) by regulating key cellular pathways such as nuclear hormone receptor signaling. In order to identify additional genes specifically regulated by RIP140 in BC, we performed a transcriptomic analysis after silencing its expression in MCF‐7 cells. We identified the interferon γ (IFNγ) signaling as being substantially repressed by RIP140 knockdown. Using the GBP1 (guanylate binding protein 1) gene as a reporter of IFNγ signaling, we demonstrated its robust induction by RIP140 through an ISRE motif, leading to a significant reduction of its induction upon IFNγ treatment. Furthermore, we showed that low levels of RIP140 amplified the IFNγ‐dependent inhibition of BC cell proliferation. In line with these data, reanalysis of transcriptomic data obtained in human BC samples revealed that IFNγ levels were associated with good prognosis only for BC patients exhibiting tumors expressing low levels of RIP140, thus confirming its effect on the anti‐tumor activity of IFNγ provided by our experimental data. Altogether, this study identifies RIP140 as a new regulator of IFNγ signaling in breast tumorigenesis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- IRCM, Institut de Recherche en Cancérologie de Montpellier, Montpellier, France.
- INSERM, Montpellier, France.
- Université de Montpellier, Montpellier, France.
- Institut régional du Cancer de Montpellier, Montpellier, France.
- Faculté des Sciences Pharmaceutiques, Université Toulouse III-Paul Sabatier, Toulouse, France.
- Department of Obstetrics and Gynecology, University Hospital Augsburg, Augsburg, Germany.
ORCID-Profile: Stéphan Jalaguier
Förderung
- Groupement des Entreprises Françaises dans la lutte contre le Cancer
Zitieren
APA
Jalaguier, S., Kuehn, A., Petitpas, C., Dulom, A., Jacquemont, R., Assi, C., Sixou, S., Jeschke, U., Colinge, J., & Cavaillès, V. (2025). The transcription factor RIP140 regulates interferon γ signaling in breast cancer. International Journal of Cancer, 157(1), 170-182. https://doi.org/10.1002/ijc.35405
Vancouver
Jalaguier S, Kuehn A, Petitpas C, Dulom A, Jacquemont R, Assi C, et al. The transcription factor RIP140 regulates interferon γ signaling in breast cancer. International Journal of Cancer. 2025;157(1):170-182. doi:10.1002/ijc.35405
BibTeX
@article{Jalaguier2025,
author = {Jalaguier, Stéphan and Kuehn, Axel and Petitpas, Chloé and Dulom, Arnaud and Jacquemont, Rémy and Assi, Cindy and Sixou, Sophie and Jeschke, Udo and Colinge, Jacques and Cavaillès, Vincent},
title = {The transcription factor RIP140 regulates interferon γ signaling in breast cancer},
journal = {International Journal of Cancer},
year = {2025},
volume = {157},
number = {1},
pages = {170--182},
doi = {10.1002/ijc.35405}
}
EUVIMED